The frequency of dual enrollment, in which participants enroll in multiple clinical trials at the same time in order to benefit from increased healthcare or payments, is up for debate among the Association of Clinical Research Organizations (ACRO) and industry professionals. ACRO believes dual enrollment is extremely rare, while others suggest it is a significant issue. One study done by Kerri Weingard of Accumed Research Associates found that 12% of trial subjects were dual enrolling, and other reports have found similar results. Industry professionals worry that dual enrolling not only affects patients’ safety, but compromises the quality of clinical trials. To read the lively discussion on Outsourcig-pharma.com, click here. Contact us at 317.899.9341 for help with clinical trials.
Single IRB – A Guide to the Common Rule sIRB Mandate
The sIRB requirement is active. Is your study affected?
Clinical Research Accelerated
You need high quality, timely board reviews so that you can get your study in the clinic.
Recent Posts
Pearl IRB 2023 Year-End Schedule
Snowball Sampling: Is it ethical to pay your study subjects to recruit participants on your behalf?
Improving Exempt Submissions: 7 Tips to Reduce Revision Requests
Common Rule Exceptions to the Use of a Single IRB for Multi-site Research Ends After May 11, 2023
Pearl IRB 2022 Year-End Schedule